These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21088426)

  • 1. Improved outcome after 'bottom-up' immunosuppression in liver transplant recipients with preoperative renal impairment.
    Schnitzbauer AA; Doenecke A; Sothmann JL; Loss M; Farkas SA; Hartl J; Tsui TY; Baier L; Kirchner G; Obed A; Bein T; Geissler EK; Scherer MN; Schlitt HJ
    Eur Surg Res; 2010; 45(3-4):356-67. PubMed ID: 21088426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation: impact of pretransplant renal insufficiency.
    Bahirwani R; Campbell MS; Siropaides T; Markmann J; Olthoff K; Shaked A; Bloom RD; Reddy KR
    Liver Transpl; 2008 May; 14(5):665-71. PubMed ID: 18433034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
    Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation.
    Schleicher C; Palmes D; Utech M; Bonrath E; Senninger N; Schmidt H; Wolters H
    Transplant Proc; 2010 Sep; 42(7):2572-5. PubMed ID: 20832546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus conversion for renal preservation in liver transplantation: not so fast.
    Jensen GS; Wiseman A; Trotter JF
    Liver Transpl; 2008 May; 14(5):601-3. PubMed ID: 18433068
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.
    Gomez-Camarero J; Salcedo M; Rincon D; Lo Iacono O; Ripoll C; Hernando A; Sanz C; Clemente G; Bañares R
    Transplantation; 2007 Sep; 84(6):786-91. PubMed ID: 17893613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF; Wachs ME; Trouillot TE; Bak T; Kugelmas M; Kam I; Everson G
    Liver Transpl; 2001 May; 7(5):401-8. PubMed ID: 11349259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
    Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
    Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients.
    Gross CR; Savik SK; Ascher NL; Gordon RD; Klintmalm GB; Payne W; Shaw BW; Strasburg K; Parker A; Wiesner RH
    Transplant Proc; 1994 Oct; 26(5):2686-90. PubMed ID: 7940841
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term outcome of immunosuppression withdrawal after liver transplantation.
    Girlanda R; Rela M; Williams R; O'Grady JG; Heaton ND
    Transplant Proc; 2005 May; 37(4):1708-9. PubMed ID: 15919439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation: impact of pretransplant renal insufficiency.
    Pham PT; Wilkinson AH
    Liver Transpl; 2008 May; 14(5):592-5. PubMed ID: 18433066
    [No Abstract]   [Full Text] [Related]  

  • 18. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
    J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.